Shots:

• The P-I dose-escalation study will assess the safety- tolerability- and preliminary efficacy of DS-1055 in adult patients with r/r advanced or metastatic head and neck- gastric and esophageal cancers- and other tumor types
• The focus of the study is to determine the maximum tolerated dose and recommended dose of DS-1055 for further study and is expected to enroll ~40 patients across the US and Japan. The company will integrate novel technologies with expertise in Ab biology to develop clinical candidates
• DS-1055 is a mAb designed to target GARP and to promote antitumor immunity through the depletion of GARP positive Tregs

 ­ Ref: Daiichi Sankyo | Image: Medical Dialogues